Summary of Product Characteristics Updated 10-Nov-2026 | McNeil Products Ltd
Daktacort Hydrocortisone Cream
Miconazole nitrate 2% w/w; Hydrocortisone acetate equivalent to hydrocortisone 1% w/w.
Excipients with known effect:
2 mg/g of benzoic acid (E210)
0.052 mg/g of butylhydroxyanisole (E320).
For the full list of excipients, see section 6.1
Cream.
White, homogeneous, odourless cream
Athlete's foot and candidal intertrigo where there are co-existing symptoms of inflammation.
Organisms which are susceptible to miconazole are dermatophytes and pathogenic yeasts (e.g., Candida spp.). Also many Gram-positive bacteria including most strains of Streptococcus and Staphylococcus.
The properties of miconazole/hydrocortisone indicate it particularly for the initial stages of treatment. Once the inflammatory symptoms have disappeared, treatment can be continued with miconazole cream or miconazole powder.
For topical administration
Apply the cream twice a day to the affected area, rubbing in gently until the cream has been absorbed by the skin.
The maximum period of treatment is 7 days.
Elderly
Natural thinning of the skin occurs in the elderly, hence corticosteroids should be used sparingly and for short periods of time.
Hypersensitivity to the active ingredients or other imidazole derivatives, or to any of the excipients listed in section 6.1.
Tubercular or viral infections of the skin or those caused by Gram-negative bacteria.
Miconazole/hydrocortisone should not be used in the following conditions:
• If the skin is broken
• On large areas of skin
• Used for longer than 7 days
• To treat cold sores and acne
• Use on the face, eyes and mucous membranes
• Children under 10 years of age, unless prescribed by a doctor
• On the ano-genital region unless prescribed by a doctor
• To treat ringworm unless prescribed by a doctor
• To treat secondary infected conditions unless prescribed by a doctor
When miconazole/hydrocortisone is used by patients taking oral anticoagulants, the anticoagulant effect should be carefully monitored.
Severe hypersensitivity reactions, including anaphylaxis and angioedema, have been reported during treatment with miconazole/hydrocortisone and other miconazole topical formulations (See section 4.8).
If a reaction suggesting hypersensitivity or irritation should occur, the treatment should be discontinued.
Miconazole/hydrocortisone must not come into contact with the mucosa of the eyes.
Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.
As with any topical corticosteroid, caution is advised when miconazole/hydrocortisone is to be applied to extensive surface areas or under occlusive dressings including baby napkins; similarly, application to the face should be avoided.
Long term continuous topical corticosteroid therapy should be avoided. Adrenal suppression can occur even without occlusion.
Because of its corticosteroid content avoid long-term treatment with miconazole/hydrocortisone. Once the inflammatory symptoms have disappeared treatment may be continued with miconazole cream or miconazole powder (see section 4.1).
Contact should be avoided between latex products such as contraceptive diaphragms or condoms and miconazole/hydrocortisone since the constituents of miconazole/hydrocortisone may damage the latex.
Miconazole/hydrocortisone can damage certain synthetic materials. Therefore, it is recommended to wear cotton underwear if this clothing comes into contact with the affected area.
This medicine contains 2 mg/g of Benzoic acid (E210) which may cause local irritation.
This medicine also contains 0.052 mg/g of Butylhydroxyanisole (E320) which may cause local skin reactions (e.g., contact dermatitis), or irritation to the eyes and mucous membranes.
Miconazole administered systemically is known to inhibit CYP3A4/2C9, which can lead to prolonged effects of warfarin or other vitamin K antagonists. While systemic absorption is limited with topical formulations, the concomitant use of Daktacort Hydrocortisone Cream and warfarin or other vitamin K antagonists should be done with caution and the anticoagulant effect should be carefully monitored and titrated. Patients should be advised of the symptoms of bleeding events and to immediately stop treatment with miconazole and seek medical advice should they occur (see section 4.5).
If symptoms persist or get worse, or if new symptoms occur, stop use and consult a doctor.
Miconazole administered systemically is known to inhibit CYP3A4/2C9. Due to the limited systemic availability after topical application, clinically relevant interactions are rare. However, in patients on warfarin or other vitamin K antagonists, caution should be exercised and anticoagulant effect should be monitored.
Miconazole is a CYP3A4 inhibitor that can decrease the rate of metabolism of hydrocortisone. Serum concentrations of hydrocortisone may be higher with the use of miconazole/hydrocortisone compared with topical preparations containing hydrocortisone alone.
Pregnancy
Caution is recommended during pregnancy. Treatment of large surfaces and the application under occlusive dressing should be avoided during that time.
Miconazole has not been observed to be teratogenic in animals but has been shown to be embryotoxic at maternal toxic doses. In animals, corticosteroids are known to cross the placenta and consequently can affect the foetus (see Section 5.3).
Breastfeeding
There are no adequate and well-controlled studies on the topical administration of miconazole/hydrocortisone during lactation. It is not known whether concomitant topical administration of miconazole/hydrocortisone to the skin could result in sufficient systemic absorption to produce detectable quantities of hydrocortisone and miconazole in breast milk in humans. Caution is recommended during breast-feeding. Treatment of large surfaces and the application under occlusive dressing should be avoided during that time.
Patients who are pregnant or breastfeeding should seek advice from a doctor before using miconazole/hydrocortisone.
It is not known if the combination of miconazole and hydrocortisone has an effect on the ability to drive or use machines.
The safety of miconazole/hydrocortisone was evaluated in 480 patients who participated in 13 clinical trials (six double-blind and seven open-label trials) of miconazole/hydrocortisone. These studies examined patients from 1 month to 95 years of age with infections of the skin caused by dermatophytes or Candida species in which inflammatory symptoms were prominent.
All patients
No adverse drug reactions (ADRs) were reported by ≥ 1% of the 480 miconazole/hydrocortisone -treated patients (adult and paediatric patients combined).
Of the three ADRs identified from the 13 clinical trials of miconazole/hydrocortisone, skin irritation was reported in one clinical trial that included patients aged 17 to 84 years, skin burning sensation in two clinical trials that included patients aged 13 to 84 years, and irritability in one clinical trial of infants aged 1 to 34 months.
Paediatric population
The safety of miconazole/hydrocortisone was evaluated in 63 paediatric patients (1 month to 14 years of age) who were treated with miconazole/hydrocortisone in 3 of the 13 clinical trials noted above. One ADR term (irritability) was reported in these 3 trials. The frequency of irritability in miconazole/hydrocortisone -treated paediatric patients was common (3.2%).
All events of irritability occurred in one clinical trial of infants (aged 1 to 34 months) with napkin dermatitis. The frequency, type and severity of other ADRs in paediatric patients are expected to be similar to those in adults.
The frequency categories use the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to < 1/1,000); very rare (<1/10,000) and not known (cannot be estimated from the available data).
Table 1: Adverse Drug Reactions in Adult and Paediatric Patients Treated with Daktacort Hydrocortisone Cream
| System Organ Class | Adverse Drug Reactions | |
| Frequency Category | ||
| Uncommon (≥1/1,000 to <1/100) | Not known | |
| Immune System Disorders | Anaphylactic reaction, Hypersensitivity | |
| Eye disorders | Vision, blurred (see also section 4.4) | |
| Skin and Subcutaneous Tissue Disorders | Skin irritation, Skin burning sensation. Urticaria, Pruritus | Angioedema, Rash, Contact dermatitis, Erythema, Skin inflammation, Skin hypopigmentation, Application site reaction |
| General Disorders and Administration Site Conditions | Irritability | |
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Prolonged and excessive use can result in skin irritation, which usually disappears after discontinuation of therapy. Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects.
Keep out of reach of children. If swallowed, get medical help straight away.
Pharmacotherapeutic group: Imidazole and triazole derivatives, combinations, ATC code: D01AC20.
There is no available information regarding the pharmacodynamic properties for the combination of miconazole and hydrocortisone in humans. The information presented below describes the pharmacodynamic properties of the single active ingredients.
Miconazole
Mechanism of action
Miconazole inhibits the biosynthesis of ergosterol in fungi and changes the composition of other lipid components in the membrane, resulting in fungal cell necrosis.
Microbiology
Miconazole combines a potent antifungal activity against the common dermatophytes, yeasts and various other fungi with an antibacterial activity against certain gram-positive bacilli and cocci (e.g. Propionibacterium acnes, Staphylococcus epidermidis and Staphylococcus aureus).
Hydrocortisone
Hydrocortisone is an anti-inflammatory steroid. Its anti-inflammatory action is due to reduction in the vascular component of the inflammatory response, suppression of migration of polymorphonuclear leukocytes, and reversal of increased capillary permeability. The vasoconstrictor action of hydrocortisone may also contribute to its anti-inflammatory activity.
There is no available information regarding the pharmacokinetic properties for the combination of miconazole and hydrocortisone in humans. The information presented below describes the pharmacokinetic properties of the single active ingredients.
Absorption
Miconazole
Miconazole remains in the skin after topical application for up to 4 days. Systemic absorption of miconazole is limited, with a bioavailability of less than 1% following topical application of miconazole. Plasma concentrations of miconazole and/or its metabolites were measurable 24 and 48 hours after application.
Hydrocortisone
Approximately 3% of the dose of hydrocortisone is absorbed after application on the skin.
Distribution
Miconazole
Absorbed miconazole is bound to plasma proteins (88.2%) and red blood cells (10.6%).
Hydrocortisone
For both topical and systemic hydrocortisone, more than 90% of hydrocortisone is bound to plasma proteins.
Metabolism
Miconazole
No studies have been found describing the metabolism of topical miconazole in humans.
Hydrocortisone
Biotransformation of topical hydrocortisone primarily takes place in the skin, and the process of metabolic transformation occurs mainly in the dermis. A study showed that the quantitative yield of the metabolic conversion products of hydrocortisone in the skin is at least 10%.
Elimination
Miconazole
The small amount of miconazole that is absorbed is eliminated predominantly in faeces as both unchanged drug and metabolites over a four-day post-administration period. Smaller amounts of unchanged drug and metabolites also appear in urine.
Hydrocortisone
The half-life of hydrocortisone is about 100 minutes. Metabolism takes place in the liver and tissues and the metabolites are excreted with the urine, mostly as glucuronides, together with a very small fraction of unchanged hydrocortisone. Around 0.2 and 1.0 percent of hydrocortisone that is applied to normal skin appears in the urine over a period of ten days.
Preclinical data on the drug product (miconazole nitrate + hydrocortisone) revealed no special hazard for humans based on conventional studies of ocular irritation, dermal sensitisation, single dose oral toxicity, primary dermal irritation toxicity, and 21-day repeat dose dermal toxicity. Additional preclinical data on the individual active ingredients in this drug product reveal no special hazard for humans based on conventional studies of local irritation, single and repeated dose toxicity, genotoxicity, and for miconazole toxicity to reproduction. Miconazole has shown no teratogenic effects but is foetotoxic at high oral doses. Reproductive effects (foetotoxicity, reduced weight gain) and developmental abnormalities, specifically craniofacial effects including cleft palate have been reported with hydrocortisone in various animal models.
Macrogol 6-32 stearate and glycol stearate
Oleoyl macrogolglycerides
Liquid paraffin
Butylhydroxyanisole (E320)
Benzoic acid (E210)
Disodium edetate
Sodium hydroxide solution
Purified water
Contact should be avoided between latex products such as contraceptive diaphragms or condoms and Daktacort Hydrocortisone cream since the constituents of Daktacort may damage the latex.
2 years
Store below 25°C
Tube formed from aluminium/PE laminate with a polypropylene screw cap.
Each tube contains 15g cream.
No special requirements for disposal.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
McNeil Products Limited
1 Station Hill Square
Station Hill
Reading
RG1 1LN
UK
PL 15513/0303
24 August 2001/27 February 2009
30 October 2026
1 Station Hill Square, Station Hill, Reading, RG1 1LN
00800 555 22000